Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
JH Krystal, AP Kaye, S Jefferson… - Proceedings of the …, 2023 - National Acad Sciences
Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …
Pharmacotherapies targeting GABA-glutamate neurotransmission for treatment-resistant depression
CM Vecera, A C. Courtes, G Jones, JC Soares… - Pharmaceuticals, 2023 - mdpi.com
Treatment-resistant depression (TRD) is a term used to describe a particular type of major
depressive disorder (MDD). There is no consensus about what defines TRD, with various …
depressive disorder (MDD). There is no consensus about what defines TRD, with various …
Overcoming the myths of esketamine administration: different and not difficult
F Buchmayer, S Kasper - Frontiers in Psychiatry, 2023 - frontiersin.org
Intranasal esketamine for treatment-resistant depression has been introduced and approved
by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration …
by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration …
The rapidly shifting ketamine landscape in the US
In recent years, ketamine has been hailed as a miracle treatment for depression and related
disorders. The US Food and Drug Administration (FDA) approved the S-enantiomer of …
disorders. The US Food and Drug Administration (FDA) approved the S-enantiomer of …
The why, when, where, how, and so what of so-called rapidly acting antidepressants
AF Schatzberg, SJ Mathew - Neuropsychopharmacology, 2024 - nature.com
Developing antidepressants that are not only more effective but are rapidly acting is the Holy
Grail for psychiatry. We review multiple issues that arise in determining rapid responses in …
Grail for psychiatry. We review multiple issues that arise in determining rapid responses in …
Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
X Lan, C Wang, F Zhang, H Liu, W Li, Y Ye… - Child and Adolescent …, 2023 - Springer
Background Ketamine and its enantiomer have rapid and robust effects on depressive
symptom and suicidal ideation. Little is known about their cognitive effects in adolescents …
symptom and suicidal ideation. Little is known about their cognitive effects in adolescents …
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
Ketamine and its enantiomers represent an innovative glutamatergic agent as a treatment
for individuals with treatment-resistant depression (TRD) and major depressive disorder …
for individuals with treatment-resistant depression (TRD) and major depressive disorder …
Efficacy and safety of esketamine nasal spray in patients with treatment-resistant depression who completed a second induction period: analysis of the ongoing …
M Castro, ST Wilkinson, RK Al Jurdi, MP Petrillo, N Zaki… - CNS drugs, 2023 - Springer
Background Treatment-resistant depression (TRD) is a chronic illness requiring long-term
treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of …
treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of …
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
S Schreiber, L Keidan, CG Pick - International Journal of Molecular …, 2023 - mdpi.com
About 30% of major depression disorder patients fail to achieve remission, hence being
diagnosed with treatment-resistant major depression (TRD). Opium had been largely used …
diagnosed with treatment-resistant major depression (TRD). Opium had been largely used …
[HTML][HTML] The Neurobiology of Stress: Vulnerability, Resilience, and Major Depression: Ketamine and the neurobiology of depression: Toward next-generation rapid …
JH Krystal, AP Kaye, S Jefferson… - Proceedings of the …, 2023 - ncbi.nlm.nih.gov
Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …